SNDX-5613-0707: Expanded Access Program for SNDX-5613 in Patients with Relapsed/Refractory Acute Leukemias with Genetic Alterations Associated with HOXA Overexpression
SC-0096
What is the goal of the study?
This is a multi-site, open-label EAP intended to provide early access to treatment with SNDX-5613 for patients with R/R leukemias, including those harboring an MLL/KMT2A gene rearrangement, NUP98, NPM1c mutation, or any other genetic alteration with overexpression of HOXA genes predicted to potentially respond to menin inhibitors, who are not eligible for a clinical study, have no other treatment options, and, in the opinion of the treating physician, would potentially benefit from treatment with SNDX-5613. Patients who are currently being treated with SNDX-5613 through a Syndax-sponsored clinical trial and have successfully completed the requirements of the clinical trial may also be considered for this EAP.
Who can participate in the study?
Please contact the study team listed below to learn more.